Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

N Andreasen; Lennart Minthon; E Vanmechelen; H Vanderstichele; P Davidsson; B Winblad; K Blennow

doi:10.1016/S0304-3940(99)00617-5

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

N Andreasen, Lennart Minthon, E Vanmechelen, H Vanderstichele, P Davidsson, B Winblad, K Blennow

Institutionen för kliniska vetenskaper, Malmö

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Sammanfattning

We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

Originalspråk	engelska
Sidor (från-till)	5-8
Tidskrift	Neuroscience Letters
Volym	273
Nummer	1
DOI	https://doi.org/10.1016/S0304-3940(99)00617-5
Status	Published - 1999

Ämnesklassifikation (UKÄ)

Neurovetenskaper

Tillgång till dokument

10.1016/S0304-3940(99)00617-5

Citera det här

@article{6cfde8002612489798c85486614d215a,

title = "Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment",

abstract = "We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.",

author = "N Andreasen and Lennart Minthon and E Vanmechelen and H Vanderstichele and P Davidsson and B Winblad and K Blennow",

year = "1999",

doi = "10.1016/S0304-3940(99)00617-5",

language = "English",

volume = "273",

pages = "5--8",

journal = "Neuroscience Letters",

issn = "0304-3940",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

AU - Andreasen, N

AU - Minthon, Lennart

AU - Vanmechelen, E

AU - Vanderstichele, H

AU - Davidsson, P

AU - Winblad, B

AU - Blennow, K

PY - 1999

Y1 - 1999

N2 - We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

AB - We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

U2 - 10.1016/S0304-3940(99)00617-5

DO - 10.1016/S0304-3940(99)00617-5

M3 - Article

SN - 0304-3940

VL - 273

SP - 5

EP - 8

JO - Neuroscience Letters

JF - Neuroscience Letters

IS - 1

ER -

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Sammanfattning

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Fingeravtryck

Citera det här